USPTO Examiner HAGHIGHATIAN MINA - Art Unit 1616

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18969037PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUMDecember 2024November 2025Allow1120YesNo
18965257DRY POWDER ESKETAMINE COMPOSITION FOR USE IN THE TREATMENT OF BIPOLAR DEPRESSION BY PULMONARY ADMINISTRATIONDecember 2024September 2025Allow910YesNo
18486860VIP and VIP Agonists, Nanoparticles, and Uses in Inflammatory T-Cell Mediated DiseaseOctober 2023March 2026Allow2910YesNo
18282137COSMETIC PRODUCT WITH SURFACE DECORATION OF DYNAMIC IMAGESSeptember 2023February 2026Allow2910NoNo
18465067POST-EMERGENCE HERBICIDESeptember 2023February 2026Allow2920NoNo
18233409ANTIMICROBIAL SILVER IODATEAugust 2023March 2025Allow1910YesNo
18446645CONTROLLING WATER RELEASE FROM A DIMENSIONALLY STABLE AQUEOUS COMPOSITIONAugust 2023June 2025Allow2210YesNo
18361242METFORMIN INHALATION POWDER AEROSOL FOR TREATING IDIOPATHIC PULMONARY FIBROSIS AND PREPARATION METHOD THEREOFJuly 2023December 2025Allow2910NoNo
18346642KITS FOR MANUFACTURING INHALABLE FORMULATIONS OF MEDICINAL CANNABIS COMPOUNDS FOR AEROSOL DEVICES, APPARATUSES, AND METHODS FOR MAKING AND USING THE SAMEJuly 2023June 2025Abandon2310NoNo
18217105TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATIONJune 2023April 2025Allow2110NoNo
18201776PRESSED POWDER PRODUCT AND METHOD FOR PREPARING THE SAMEMay 2023January 2026Allow3210NoNo
18310647NASAL DELIVERYMay 2023April 2025Abandon2410NoNo
18310311Nanostructured Gels Capable of Controlled Release of Encapsulated AgentsMay 2023February 2025Abandon2210NoNo
18307860ANTIMICROBIAL COMPOSITIONApril 2023May 2025Allow2420YesNo
18139031INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATEApril 2023February 2025Allow2120YesNo
18033349METHOD FOR PREPARING ANTIMICROBIAL TREATMENT AGENT FOR TEXTILEApril 2023March 2026Allow3520NoNo
18248056INHALATION FORMULATION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFApril 2023February 2026Abandon3501NoNo
18190614EUTECTIC SOLVENTS COMPRISING PHARMACEUTICAL AGENTS, AND METHODS OF MAKING AND USE THEREOFMarch 2023June 2025Abandon2720NoNo
18024821POWDER COMPOSITION BASED ON MICROPARTICLES EMBEDDING NANOPARTICLES FOR THE DELIVERY OF THERAPEUTIC/DIAGNOSTIC COMPOUNDSMarch 2023March 2025Allow2431YesNo
18116690METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTSMarch 2023February 2025Abandon2420NoNo
18113384POLYMERIC PARTICLES CONTAINING MICROORGANISMSFebruary 2023October 2024Allow2010NoNo
18110273COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONSFebruary 2023June 2024Allow1610YesNo
18106948Diketopiperazine Microparticles with Defined Specific Surface AreasFebruary 2023May 2025Allow2740NoNo
18153096AEROSOL FORMULATION FOR COPDJanuary 2023March 2025Allow2621YesNo
18015577A POLYHERBAL METALLO-MINERAL PHARMACEUTICAL KITJanuary 2023December 2025Allow3520YesNo
18145471Systems, Methods and Products for Minimizing Tissue Reactions and Tissue Injury at an Infusion SiteDecember 2022June 2024Allow1710NoNo
18011770MULTI-LAYERED MEDICAMENT FOR INHALATIONDecember 2022September 2025Allow3310NoNo
18075627THERAPEUTIC AGENT DELIVERY SYSTEMS AND METHODS OF FORMING AND USES THEREOFDecember 2022October 2025Abandon3510NoNo
18057486DELIVERY DEVICE AND FORMULATIONNovember 2022April 2024Allow1710NoNo
17988263ENGINEERED METAL NANOPARTICLES AND METHODS THEREOFNovember 2022November 2024Abandon2420NoNo
17998308NOVEL INHALANTNovember 2022October 2025Abandon3510NoNo
17976737DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITISOctober 2022June 2024Abandon1910NoNo
17972435EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINEOctober 2022July 2024Allow2120NoNo
17963176Peramivir Dry Powder Inhaler and Method of Preparing the SameOctober 2022February 2026Abandon4010NoNo
17936560FUNGICIDAL COMBINATIONSSeptember 2022April 2025Allow3130YesNo
17911523TREATMENT WITH POWDERED INTRANASAL EPINEPHRINESeptember 2022March 2026Allow4220NoNo
17906241GOLD-CONTAINING AGENTS FOR THE TREATMENT OF LUNG INFECTIONSSeptember 2022November 2025Allow3820YesNo
17823336MONOCLONAL ANTIBODY DRY POWDERSAugust 2022May 2025Abandon3221NoNo
17893612COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATIONAugust 2022September 2023Allow1310NoNo
17886124Inhalable Epinephrine FormulationAugust 2022March 2024Allow1930YesNo
17885487NOVEL AEROSOL FORMULATIONS OF ONDANSETRON AND USES THEREOFAugust 2022December 2023Abandon1610NoNo
17882132COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUSAugust 2022November 2023Abandon1510NoNo
17877937ANTIHISTAMINE AND ANTI-MICROBIAL NASAL SOLUTIONS AND RELATED METHODSJuly 2022July 2024Abandon2420NoNo
17816207FLEXIBLE COLOR SUBSTATEJuly 2022July 2024Allow2421YesNo
17816220BONDABLE MICROCAPSULES AND SURFACE FUNCTIONALIZED FILLERSJuly 2022August 2023Allow1210YesNo
17871232NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHIJuly 2022September 2024Abandon2620YesNo
17861072COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERYJuly 2022March 2024Abandon2030YesNo
17810941POST-EMERGENCE HERBICIDEJuly 2022September 2023Abandon1510NoNo
17834583INTRANASAL DHE FOR THE TREATMENT OF HEADACHEJune 2022December 2025Allow4240YesNo
17744333Transdural Drug Delivery SystemMay 2022February 2024Abandon2141YesNo
17737434INHALABLE PARTICLESMay 2022July 2023Allow1410YesNo
17724474Lung-targeted corticosteroid treatment in viral respiratory disease, COVID-19 and ARDS (acute respiratory distress syndrome)April 2022September 2024Abandon2921NoNo
17699405LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOFMarch 2022December 2025Abandon4550NoNo
17695155Inhalable dry powder pharmaceutical compositionMarch 2022January 2024Abandon2201NoNo
17694056METHOD FOR CULTIVATING CITRUS PLANTMarch 2022June 2025Abandon3940YesNo
17694101METHOD FOR CULTIVATING CITRUS PLANT AND LIQUID COMPOSITIONMarch 2022May 2025Abandon3840YesNo
17685704NEBULIZED IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOFMarch 2022March 2025Abandon3721NoYes
17590051LIPOPHILIC COSMETIC COMPOSITIONS CONTAINING PELARGONIC ACID ESTERSFebruary 2022June 2024Allow2820NoNo
17574052HERBICIDAL COMBINATIONJanuary 2022September 2023Abandon2001NoNo
17547635METHOD OF USING COMPOSITION FOR TREATMENT OF VEISALGIADecember 2021April 2024Abandon2820NoNo
17456271BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODSNovember 2021August 2023Allow2120NoNo
17595463FUNCTIONAL FIBROUS MATERIAL COMPRISING MICROBIAL FLAKES, METHODS OF PREPARING AND USES THEREOFNovember 2021July 2025Allow4420YesNo
17528011INHALED IMATINIB FOR PULMONARY HYPERTENSIONNovember 2021March 2026Abandon5241YesYes
17611746CHEMICAL COMPOSITION FOR SEED TREATMENTNovember 2021August 2025Allow4520YesNo
17523229POWDER INJECTION OF THE DONEPEZIL SEMI PALMOXIRIC ACID SALT, COMPOSITION CONTAINING SAME AND PREPARATION METHOD THEREFORNovember 2021July 2023Allow2010YesNo
17517157Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)November 2021March 2024Abandon2911NoNo
17506190Methods and Compositions for Spray Drying Gram-Negative BacteriaOctober 2021October 2024Abandon3530YesNo
17494885ANTIMICROBIAL COMPOSITIONOctober 2021December 2023Abandon2620NoNo
17489128LINEAR POLYSACCHARIDE BASED FILM PRODUCTSSeptember 2021December 2025Allow5050YesNo
17439385PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANES AND METHODS FOR PRODUCING SAMESeptember 2021May 2025Allow4420YesNo
17470788TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATIONSeptember 2021March 2023Allow1810NoNo
17465911DISINFECTANT-DOSING MICROGEL AND METHOD OF USING THE SAMESeptember 2021August 2025Abandon4821NoNo
17465126EXPANDABLE MICROCAPSULESeptember 2021November 2024Abandon3810NoNo
17410774Inhalable Formulation of Fluticasone Propionate and Albuterol SulfateAugust 2021January 2023Allow1731YesNo
17405773LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOFAugust 2021December 2025Abandon5250NoNo
17400897ANTIMICROBIAL SILVER IODATEAugust 2021May 2023Allow2120NoNo
17392824METHODS AND MATERIALS FOR TREATING LUNG DISORDERSAugust 2021August 2024Allow3630YesNo
17371603NON-THERAPEUTIC METHOD, USES OF A SUBSTANCE THAT STIMULATES OR GENERATES AN INCREASE IN VOLUMEJuly 2021July 2023Abandon2510NoNo
17352076Disinfection Composition and Preparation Method Therefor and Use ThereofJune 2021July 2022Allow1321YesNo
17345830METHOD OF USING NEBULIZED ALCOHOL FOR ANALGESIAJune 2021August 2022Allow1420NoNo
17311153Oral Thin FilmsJune 2021October 2025Allow5241YesNo
17330485DELIVERY OF AEROSOLIZED MICROMOLAR COMPOSITION CONCENTRATIONSMay 2021May 2023Abandon2430NoYes
173272684% Trisodium Citrate Solution for Use as a Catheter Lock SolutionMay 2021August 2025Allow5120YesYes
17292226NEW COMPOSITION COMPRISING AMORPHOUS NANOPOROUS SILICA PARTICLESMay 2021December 2023Abandon3101NoNo
17290585SOLID COMPOSITION FOR PLANT CARE CONTAINING FUNGAL SCLEROTIA AND USE THEREOFApril 2021June 2025Abandon5021NoNo
17244455MULTI-PURPOSE LIGNIN-CARBOHYDRATE BINDING SYSTEMApril 2021June 2025Allow4951YesYes
17237350Combinations of Glycopyrrolate and Beta2 Adrenoceptor AgonistsApril 2021June 2023Abandon2510NoNo
17221645COMPOSITIONS COMPRISING A MANGANESE MINERAL AND METHODS OF USEApril 2021June 2023Allow2620YesYes
17281399FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATIONMarch 2021May 2024Abandon3821NoNo
17281136KETAMINE COMPOSITION FOR USE IN A METHOD OF TREATMENT OF DEPRESSION BY PULMONARY ADMINISTRATIONMarch 2021November 2023Allow3111YesNo
17215249N-MYC-INTERACTOR PROTEIN AS A MARKER FOR CHRONIC LUNG DISEASE AND USES THEREOFMarch 2021November 2023Allow3111YesNo
17214416AEROSOLIZED FLUOROQUINOLONES AND USES THEREOFMarch 2021May 2023Abandon2610NoNo
17280452PHARMACEUTICAL COMPOSITIONS COMPRISING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATIONMarch 2021April 2024Abandon3630NoNo
17207442COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONSMarch 2021September 2021Allow610NoNo
17207467COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONSMarch 2021September 2021Allow610NoNo
17205304SEED PRE-SOAK TECHNOLOGY WITH A DROP OF HEMATITE NANOPARTICLE FERTILIZER FOR INCREASED PLANT GROWTHMarch 2021June 2025Allow5131YesNo
17275086PHARMACEUTICAL COMPOSITION OF CHLORINE FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONMarch 2021September 2024Abandon4340NoNo
17192764METHODS OF MULTI-SPECIES INSECT PEST CONTROLMarch 2021November 2024Allow4421YesNo
17186561Inhalable Formulation of a Solution Containing Glycopyrronium BromideFebruary 2021June 2022Abandon1520YesNo
17269642CANNABINOID-CONTAINING PRODUCTS, CONTAINERS, SYSTEMS, AND METHODSFebruary 2021October 2024Abandon4401NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAGHIGHATIAN, MINA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
48
Examiner Affirmed
36
(75.0%)
Examiner Reversed
12
(25.0%)
Reversal Percentile
37.6%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
187
Allowed After Appeal Filing
25
(13.4%)
Not Allowed After Appeal Filing
162
(86.6%)
Filing Benefit Percentile
16.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HAGHIGHATIAN, MINA - Prosecution Strategy Guide

Executive Summary

Examiner HAGHIGHATIAN, MINA works in Art Unit 1616 and has examined 1,262 patent applications in our dataset. With an allowance rate of 50.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner HAGHIGHATIAN, MINA's allowance rate of 50.8% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HAGHIGHATIAN, MINA receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HAGHIGHATIAN, MINA is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +22.6% benefit to allowance rate for applications examined by HAGHIGHATIAN, MINA. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.3% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 53.8% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 66.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 52.4% are granted (fully or in part). This grant rate is in the 52% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.5% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.